Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-350448
Filing Date
2026-08-14
Accepted
2026-08-14 08:00:38
Documents
65
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pmvp-20260630.htm   iXBRL 10-Q 2004060
2 EX-31.1 pmvp-ex31_1.htm EX-31.1 18324
3 EX-31.2 pmvp-ex31_2.htm EX-31.2 18055
4 EX-32.1 pmvp-ex32_1.htm EX-32.1 10044
5 EX-32.2 pmvp-ex32_2.htm EX-32.2 10337
  Complete submission text file 0001193125-26-350448.txt   8177119

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pmvp-20260630.xsd EX-101.SCH 1026725
69 EXTRACTED XBRL INSTANCE DOCUMENT pmvp-20260630_htm.xml XML 1479718
Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Filer) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39539 | Film No.: 261276230
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)